Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLS-1200 for prevention of acute rhinosinusitis after FESS
NCT04060316Phase 2Unknown
- Sponsor
- GeneOne Life Science, Inc.
- Start
- Dec 2023
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of quinine in acute rhinosinusitis (ARS) (2 arms), sponsored by GeneOne Life Science, Inc. Primary endpoints: Treatment emergent adverse events at 16 weeks and Incidence of post-operative acute rhinosinusitis at 16 weeks. Status: unknown.
02
Drugs
quinine
03
Conditions
acute rhinosinusitis (ARS)
Beyond the preview
Go deeper on NCT04060316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04060316.